Climb Bio to Host Virtual Investor Event on October 15, 2024
October 03 2024 - 9:00AM
Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a
virtual investor day on October 15, 2024. The event will feature
members of Climb Bio’s management team and an external expert who
will provide an update to the investment community on the Company’s
strategy and focus on developing therapeutics for immune-mediated
diseases.
Climb Bio’s virtual investor event will include presentations
from Aoife Brennan, M.B., Ch.B., President and Chief Executive
Officer, Stephen Thomas, Ph.D., Member of Climb Bio’s Board and
Co-founder of Tenet Medicines, Jan Hillson, M.D., Senior Clinical
Advisor, Nishi Rampal, M.D., Senior Vice President, Clinical
Development, and Brett Kaplan, M.D., Chief Operating Officer as
well as presentations from a key opinion leader, Frank Cortazar,
Director of the New York Nephrology Vasculitis and Glomerular
Center.
The event will provide an in-depth review of Climb Bio’s lead
asset, budoprutug, an anti-CD19 monoclonal antibody that is
designed to treat a broad range of immune-mediated diseases,
including systemic lupus erythematosus, immune thrombocytopenia and
membranous nephropathy and has demonstrated B-cell depletion in
early clinical trials.
Register for the event here.
A live webcast of the event, as well as a replay, will be
available under "Events and Presentations" in the Investors section
of the Company's website: climbbio.com
About Climb Bio, Inc. Climb Bio, Inc., is a
clinical-stage biotechnology company developing therapeutics for
patients with immune-mediated diseases. The Company’s lead product
candidate, budoprutug, is an anti-CD19 monoclonal antibody that has
demonstrated B-cell depletion and has potential to treat a broad
range of B-cell mediated diseases. For more information, please
visit climbbio.com.
InvestorsChris Brinzey ICR
Westwickechris.brinzey@westwicke.com 339-970-2843
MediaJon YuICR
Westwickejon.yu@westwicke.com475-395-5375
Climb Bio (NASDAQ:CLYM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Climb Bio (NASDAQ:CLYM)
Historical Stock Chart
From Dec 2023 to Dec 2024